Milton B Yatvin

US Patent:

6339060, Jan 15, 2002

Filed:

May 16, 2000

Appl. No.:

09/573497

Inventors:

Milton B. Yatvin - Portland OR
Michael H B Stowell - Cambridge, GB
Vincent S. Gallicchio - Lexington KY
Michael J. Meredith - Lake Oswego OR

Assignee:

Oregon Health Science University - Portland OR

International Classification:

A01N 3718

US Classification:

514 2, 424450, 435176, 435178, 435179, 435180, 435325, 435366, 530300, 530329, 530331, 530811, 530813, 530814, 530815

Abstract:

Methods and reagents are provided for specifically targeting biologically active compounds such as antiviral and antimicrobial drugs, or prodrugs containing the biologically active compound to specific sites such as specific organelles in phagocytic mammalian cells. The biologically active compound or prodrug is linked to a microparticle with a linker that is non-specifically or specifically cleaved inside a phagocytic mammalian cell. Alternatively, the biologically active compound or prodrug is impregnated into a porous microparticle or coated on a nonporous microparticle, and then coated with a coating material that is non-specifically or specifically degraded inside a phagocytic mammalian cell. The prodrug contains the biologically active compound linked to a polar lipid such as ceramide with a specific linker such as a peptide that is specifically cleaved to activate the prodrug in a phagocytic mammalian cell infected with a microorganism. A microparticle linked antimicrobial drug or prodrug may be used for killing a microorganism infecting a phagocytic mammalian cell in vivo or in vitro.

US Patent:

6387876, May 14, 2002

Filed:

Oct 12, 1999

Appl. No.:

09/415640

Inventors:

Milton B. Yatvin - Portland OR
Michael HB Stowell - Padadena CA

Assignee:

Oregon Health and Science University - Portland OR

International Classification:

A61K 3800

US Classification:

514 2, 514 51, 514 78

Abstract:

This invention herein describes a method of facilitating the entry of drugs into cells and tissues at pharmokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods because through this method, intracellular drug concentrations may reach levels which are orders of magnitude higher than those achieved otherwise. Furthermore, it refines the drug delivery process by allowing therapeutic agents to be directed to certain intracellular structures. This technology is appropriate for use with antiproliferative, antibiotic, antimycotic, antiviral and antineoplastic drugs, in particular in combination with a multiplicity of other emollients and agents to make up topically-active substances such as salves, for rapid and efficient introduction of such agents through the epidermis for treatment of skin diseases and other disorders.

US Patent:

6436437, Aug 20, 2002

Filed:

Feb 15, 2000

Appl. No.:

09/503892

Inventors:

Milton B. Yatvin - Portland OR
Michael H. B. Stowell - Pasadena CA
Michael J. Meredith - Lake Oswego OR

Assignee:

Oregon Health and Science University - Portland OR

International Classification:

A61K 9127

US Classification:

424450, 514 2, 514649, 514212, 5142222, 5142235, 5142248, 5142275

Abstract:

This invention herein describes a method of facilitating the entry of drugs into cells and tissues at physiologically protected sites at pharmicokinetically useful levels and also a method of targeting drugs to specific organelles within the cell. This polar lipid/drug conjugate targeting invention embodies an advance over other drug targeting methods known in the prior art, because the invention provides drug concentrations in such physiologically protected sites that can reach therapeutically-effective levels after administration of systemic levels much lower than are currently administered to achieve a therapeutic dose. This technology is appropriate for use with psychotropic, neurotropic and neurological drugs, agents and compounds, for rapid and efficient introduction of such agents across the blood-brain barrier. Further, the invention provides means for retention and prolonged enzymatic release of psychotropic, neurotropic and neurological drugs, agents and compounds comprising the conjugates of the invention, in the brain and central nervous system.

US Patent:

6455073, Sep 24, 2002

Filed:

Jul 10, 2000

Appl. No.:

09/612732

Inventors:

Michael J. Meredith - Lake Oswego OR
Milton B. Yatvin - Portland OR
Richard L. Pederson - San Gabriel CA

Assignee:

Enzrel, Inc. - Portland OR

International Classification:

A61K 914

US Classification:

424490, 424489, 424491

Abstract:

This invention provides reagents and methods for specifically delivering antibiotic, antimicrobial and antiviral compounds, drugs and agents to phagocytic mammalian cells. The invention also relates to specific delivery to and uptake of such compounds by phagocytic cells. The invention specifically relates to reagents and methods for facilitating the entry of antibiotic, antimicrobial and antiviral compounds, drugs and agents into phagocytic cells. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising such antibiotic, antimicrobial or antiviral compounds, drugs and agents conjugated to, impregnated with or coated onto particulate carriers generally termed microparticles. In particular embodiments, the antibiotic, antimicrobial and antiviral compounds, drugs and agents are covalently linked to a microparticle via a specifically-degradable linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Also provided are porous microparticles impregnated with antibiotic, antimicrobial or antiviral compounds, drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell.

US Patent:

6664257, Dec 16, 2003

Filed:

Nov 5, 2001

Appl. No.:

09/993974

Inventors:

Milton B. Yatvin - Portland OR
Richard L. Pederson - San Gabriel CA

Assignee:

EnzRel Inc. - Portland OR

International Classification:

A61K 3150

US Classification:

514247, 5142521

Abstract:

This invention provides compositions of matter, pharmaceutical compounds, methods of synthesizing such compounds and methods for using such compounds to treat animals infected with a pathogenic mycobacterium. The invention specifically provides compositions and pharmaceutical compositions thereof for the treatment of tuberculosis and other Mycobacterium-caused diseases.

US Patent:

6676972, Jan 13, 2004

Filed:

Sep 9, 2002

Appl. No.:

10/237846

Inventors:

Michael J. Meredith - Lake Oswego OR
Milton B. Yatvin - Portland OR
Richard L. Pederson - San Gabriel CA

Assignee:

Oregon Health and Science University - Portland OH

International Classification:

A61K 914

US Classification:

424490, 424489, 424491

Abstract:

This invention provides reagents and methods for specifically delivering antibiotic, antimicrobial and antiviral compounds, drugs and agents to phagocytic mammalian cells. The invention also relates to specific delivery to and uptake of such compounds by phagocytic cells. The invention specifically relates to reagents and methods for facilitating the entry of antibiotic, antimicrobial and antiviral compounds, drugs and agents into phagocytic cells. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising such antibiotic, antimicrobial or antiviral compounds, drugs and agents conjugated to, impregnated with or coated onto particulate carriers generally termed microparticles. In particular embodiments, the antibiotic, antimicrobial and antiviral compounds, drugs and agents are covalently linked to a microparticle via a specifically-degradable linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Also provided are porous microparticles impregnated with antibiotic, antimicrobial or antiviral compounds, drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell.

US Patent:

6689760, Feb 10, 2004

Filed:

Jul 10, 2000

Appl. No.:

09/613409

Inventors:

Milton B. Yatvin - Portland OR
Richard L. Pederson - San Gabriel CA

Assignee:

EnzRel Inc. - Portland OR

International Classification:

A61K 3170

US Classification:

514 45, 514 47, 536 2624

Abstract:

This invention provides compositions of matter, pharmaceutical compounds, methods of synthesizing such compounds and methods for using such compounds to treat animals infected with a pathogenic mycobacterium. The invention specifically provides compositions and pharmaceutical compositions thereof for the treatment of tuberculosis and other Mycobacterium-caused diseases.

US Patent:

6761901, Jul 13, 2004

Filed:

May 2, 2000

Appl. No.:

09/562207

Inventors:

Guru V. Betageri - Chino Hills CA
Milton B. Yatvin - Portland OR

Assignee:

EnzRel Inc. - Portland OR

International Classification:

A61K 9127

US Classification:

424450, 424458, 424462, 424463, 424469, 424474, 424475, 424480, 424482

Abstract:

This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration.